SHINE Medical announces that its isotope production facility is weathertight

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210325005847/en/

SHINE executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. (Photo: SHINE Medical Technologies)

Reaching the weathertight milestone moves SHINE one step closer to providing a flexible, reliable supply of molybdenum-99 (Mo-99) and other neutron-produced isotopes to customers, physicians and patients. It means that the 46,000-square-foot building is now sealed against the elements and the installation of SHINE’s high-tech process equipment can begin. The production facility has been built to withstand tornados, airplane crashes and other catastrophic events, and is expected to be a major producer of medicine for decades to come.

“This milestone marks a leveling-up for our team, which includes our internal staff, but also all those who helped do the work in the field,” said Greg Piefer, founder and CEO of SHINE. “We’ve now demonstrated we can execute against a challenging first-of-a-kind nuclear build and do so within schedule and budget contingencies— all during a global pandemic. I am incredibly proud of the grit, dedication and skill of all those involved as we worked together to tackle complicated problems in challenging conditions. The results of the team’s hard work say a lot about their extraordinary dedication, talent and commitment to improving the lives of patients everywhere.”

Please click here to view a short video about SHINE’s achievement of this milestone.

The plant is expected to be the largest medical isotope production facility in the world by capacity. SHINE is installing the specialized process equipment in the facility during the next year, and expects to begin producing Mo-99 in late 2022.

“Baker Concrete Construction is proud to be one of SHINE’s partner in the construction of this important facility and we’re excited to have been given the opportunity to play a key role in getting the project to weathertight,” said Matt Jorn, project executive of Baker. “We understand what this plant means, not just to SHINE, but to patients around the globe. This commitment makes our involvement in the facility’s construction even more meaningful. Doing our part to bring the facility to weathertight is something that the entire Baker team takes great pride in.”

In addition to Baker, SHINE’s construction partners include J.H. Findorff & Son Inc., Sargent & Lundy LLC, Lycon Inc., and Westphal & Co.

About SHINE Medical Technologies

SHINE is a nuclear technology company committed to improving the lives of patients around the world. The company is focused initially on the commercialization of medical isotopes, including molybdenum-99, a diagnostic isotope used to diagnose heart disease, cancer and other diseases, and lutetium-177, a therapeutic isotope that holds the promise of significantly improving the outcomes for some cancer patients. SHINE has created isotope production processes that will deliver products to benefit physicians and patients and help solve critical supply problems in the United States and markets in Europe and around the world. SHINE has a long-term strategy to solve some of humanity’s biggest problems and advance our vision for progressively broad and impactful uses of nuclear technology. For more information, please visit our website at www.shinemed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005847/en/